Navigation Links
China Cord Blood Corporation Announces Completion of Strategic Partnership with Cordlife Group Limited
Date:11/12/2012

HONG KONG, Nov. 12, 2012 /PRNewswire-FirstCall/ -- China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"), the first and largest cord blood banking operator in China, today announced the successful completion of the transaction with Cordlife Group Limited (CLGL.SP) ("Cordlife"), a cord blood and tissue banking service provider listed on the Singapore Exchange Securities Trading Limited ("SGX-ST").  The transaction was first announced on August 15, 2012.

As a result of the transaction, CCBC now wholly owns the equity ownership of Guangzhou Municipality Tianhe Nuoya Bio-engineering Co. Ltd. ("Nuoya"), the Company's operating arm in Guangdong province, and Cordlife acquired 7,314,015 ordinary shares of the Company, representing approximately 10% of the Company's issued and outstanding shares.  As of the date of this press release, the Company has 73,140,147 issued shares (inclusive of 100,999 shares being held as treasury shares).

For the purpose of fostering a close alliance and building partnership between CCBC and Cordlife, the board of directors of CCBC has appointed Mr. Jeremy Yee as a non-executive independent director, effective today.  Mr. Yee serves as the Chief Executive Officer of Cordlife and is experienced with developing successful growth strategies in Pan-Asia regions.  Mr. Yee holds a BA (Econ)(Hons) from the University of Manchester and a BCom (Prof Acct) from Murdoch University, as well as a MCom from the University of Sydney, and a MBA from NTU and The University of Chicago Booth School of Business.   

About China Cord Blood Corporation

China Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and is the only cord blood banking operator with multiple licenses.  Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today.  China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services.  For more information, please visit the Company's website at http://www.chinacordbloodcorp.com.   

For more information, please contact:

China Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Email: ir@chinacordbloodcorp.com   

ICR, Inc.
Mr. Rob Koepp
Tel: (+86) 10-6583-7516
U.S. Tel: (646) 405-5185
Email: robert.koepp@icrinc.com


'/>"/>
SOURCE China Cord Blood Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2013 Financial Results
2. China Biologic Products to Report Third Quarter 2012 Financial Results
3. Life Technologies New State-of-the-Art Manufacturing Facility in China Provides Forensics Labs Rapid Access to World-Leading DNA Testing Solutions
4. China Cord Blood Corporation and Golden Meditech Holdings Limited Enter into Convertible Note Financing to Further Expand Cord Blood Banking Services
5. Hawaii Tech Asia Takes Hawaii & US Entrepreneurs To China
6. Orthobiologics Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018: China Market Research Reports
7. China Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2013
8. China Cord Blood Corporation to Report First Quarter of Fiscal 2013 Financial Results
9. China Cord Blood Corporation and Cordlife Group Limited Foster Closer Alliance Across Asia
10. China Biologic Reports Financial Results for the Second Quarter and First Half of 2012
11. China Cord Blood Corporation Files its Annual Report on Form 20-F
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... March 23, 2017  SeraCare Life Sciences, ... in vitro diagnostics manufacturers and clinical laboratories, ... first multiplexed Inherited Cancer reference material ... by next-generation sequencing (NGS). The Seraseq™ Inherited Cancer ... input from industry experts to validate the ...
(Date:3/23/2017)...  BioPharmX Corporation (NYSE MKT: BPMX), a specialty ... today reported financial results for the quarter and ... an update on the company,s clinical development efforts ... are pleased to report that last year was ... Anja Krammer. "We achieved key clinical milestones and ...
(Date:3/23/2017)... , March 23, 2017 Kineta, Inc., ... of novel therapies in immuno-oncology, today announced the ... small molecule compounds that activate interferon response factor ... and demonstrate immune-mediated tumor regression in a murine ... study who demonstrated complete tumor regression to initial ...
(Date:3/23/2017)... 2017 According to a report by Transparency ... fragmented due to the presence of a large pool of participants; ... Fisher , and Sigma-Aldrich, compete with each other in this market. ... more than 76% of this market in 2016.  ... As of now, a large number ...
Breaking Biology Technology:
(Date:3/6/2017)... 2017 Mintigo , the leader ... Predictive Sales Coach TM , its new artificial ... into Salesforce. This unique AI application will allow ... with deep knowledge of their customers and prospects ... Predictive Sales Coach extends Mintigo,s existing customer success ...
(Date:3/2/2017)... -- Australian stem cell and regenerative medicine company, ... agreement with the Monash Lung Biology Network, a consortia ... Department of Pharmacology at Monash University, Melbourne ... support the use of Cymerus™ mesenchymal stem cells (MSCs) ... is a chronic, long term lung condition recognised by ...
(Date:2/28/2017)... Spanien, 27. Februar 2017  EyeLock LLC, ein marktführendes ... seine erstklassige biometrische Lösung zur Iris-Erkennung auf ... X16 LTE auf dem Mobile World Congress ... Qualcomm-Stand in Halle 3, Stand 3E10, vorstellen. ... Sicherheitsplattform Qualcomm Haven™ – eine Kombination aus ...
Breaking Biology News(10 mins):